Cargando…
New Radioligands for Describing the Molecular Pharmacology of MT(1) and MT(2) Melatonin Receptors
Melatonin receptors have been studied for several decades. The low expression of the receptors in tissues led the scientific community to find a substitute for the natural hormone melatonin, the agonist 2-[(125)I]-iodomelatonin. Using the agonist, several hundreds of studies were conducted, includin...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3676766/ https://www.ncbi.nlm.nih.gov/pubmed/23698757 http://dx.doi.org/10.3390/ijms14058948 |
_version_ | 1782272660573519872 |
---|---|
author | Legros, Céline Matthey, Ulrich Grelak, Teresa Pedragona-Moreau, Sandrine Hassler, Werner Yous, Saïd Thomas, Emmanuel Suzenet, Franck Folleas, Benoît Lefoulon, François Berthelot, Pascal Caignard, Daniel-Henri Guillaumet, Gérald Delagrange, Philippe Brayer, Jean-Louis Nosjean, Olivier Boutin, Jean A. |
author_facet | Legros, Céline Matthey, Ulrich Grelak, Teresa Pedragona-Moreau, Sandrine Hassler, Werner Yous, Saïd Thomas, Emmanuel Suzenet, Franck Folleas, Benoît Lefoulon, François Berthelot, Pascal Caignard, Daniel-Henri Guillaumet, Gérald Delagrange, Philippe Brayer, Jean-Louis Nosjean, Olivier Boutin, Jean A. |
author_sort | Legros, Céline |
collection | PubMed |
description | Melatonin receptors have been studied for several decades. The low expression of the receptors in tissues led the scientific community to find a substitute for the natural hormone melatonin, the agonist 2-[(125)I]-iodomelatonin. Using the agonist, several hundreds of studies were conducted, including the discovery of agonists and antagonists for the receptors and minute details about their molecular behavior. Recently, we attempted to expand the panel of radioligands available for studying the melatonin receptors by using the newly discovered compounds SD6, DIV880, and S70254. These compounds were characterized for their affinities to the hMT(1) and hMT(2) recombinant receptors and their functionality in the classical GTPγS system. SD6 is a full agonist, equilibrated between the receptor isoforms, whereas S70254 and DIV880 are only partial MT(2) agonists, with K(i) in the low nanomolar range while they have no affinity to MT(1) receptors. These new tools will hopefully allow for additions to the current body of information on the native localization of the receptor isoforms in tissues. |
format | Online Article Text |
id | pubmed-3676766 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Molecular Diversity Preservation International (MDPI) |
record_format | MEDLINE/PubMed |
spelling | pubmed-36767662013-07-02 New Radioligands for Describing the Molecular Pharmacology of MT(1) and MT(2) Melatonin Receptors Legros, Céline Matthey, Ulrich Grelak, Teresa Pedragona-Moreau, Sandrine Hassler, Werner Yous, Saïd Thomas, Emmanuel Suzenet, Franck Folleas, Benoît Lefoulon, François Berthelot, Pascal Caignard, Daniel-Henri Guillaumet, Gérald Delagrange, Philippe Brayer, Jean-Louis Nosjean, Olivier Boutin, Jean A. Int J Mol Sci Article Melatonin receptors have been studied for several decades. The low expression of the receptors in tissues led the scientific community to find a substitute for the natural hormone melatonin, the agonist 2-[(125)I]-iodomelatonin. Using the agonist, several hundreds of studies were conducted, including the discovery of agonists and antagonists for the receptors and minute details about their molecular behavior. Recently, we attempted to expand the panel of radioligands available for studying the melatonin receptors by using the newly discovered compounds SD6, DIV880, and S70254. These compounds were characterized for their affinities to the hMT(1) and hMT(2) recombinant receptors and their functionality in the classical GTPγS system. SD6 is a full agonist, equilibrated between the receptor isoforms, whereas S70254 and DIV880 are only partial MT(2) agonists, with K(i) in the low nanomolar range while they have no affinity to MT(1) receptors. These new tools will hopefully allow for additions to the current body of information on the native localization of the receptor isoforms in tissues. Molecular Diversity Preservation International (MDPI) 2013-04-25 /pmc/articles/PMC3676766/ /pubmed/23698757 http://dx.doi.org/10.3390/ijms14058948 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland http://creativecommons.org/licenses/by/3.0 This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Legros, Céline Matthey, Ulrich Grelak, Teresa Pedragona-Moreau, Sandrine Hassler, Werner Yous, Saïd Thomas, Emmanuel Suzenet, Franck Folleas, Benoît Lefoulon, François Berthelot, Pascal Caignard, Daniel-Henri Guillaumet, Gérald Delagrange, Philippe Brayer, Jean-Louis Nosjean, Olivier Boutin, Jean A. New Radioligands for Describing the Molecular Pharmacology of MT(1) and MT(2) Melatonin Receptors |
title | New Radioligands for Describing the Molecular Pharmacology of MT(1) and MT(2) Melatonin Receptors |
title_full | New Radioligands for Describing the Molecular Pharmacology of MT(1) and MT(2) Melatonin Receptors |
title_fullStr | New Radioligands for Describing the Molecular Pharmacology of MT(1) and MT(2) Melatonin Receptors |
title_full_unstemmed | New Radioligands for Describing the Molecular Pharmacology of MT(1) and MT(2) Melatonin Receptors |
title_short | New Radioligands for Describing the Molecular Pharmacology of MT(1) and MT(2) Melatonin Receptors |
title_sort | new radioligands for describing the molecular pharmacology of mt(1) and mt(2) melatonin receptors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3676766/ https://www.ncbi.nlm.nih.gov/pubmed/23698757 http://dx.doi.org/10.3390/ijms14058948 |
work_keys_str_mv | AT legrosceline newradioligandsfordescribingthemolecularpharmacologyofmt1andmt2melatoninreceptors AT mattheyulrich newradioligandsfordescribingthemolecularpharmacologyofmt1andmt2melatoninreceptors AT grelakteresa newradioligandsfordescribingthemolecularpharmacologyofmt1andmt2melatoninreceptors AT pedragonamoreausandrine newradioligandsfordescribingthemolecularpharmacologyofmt1andmt2melatoninreceptors AT hasslerwerner newradioligandsfordescribingthemolecularpharmacologyofmt1andmt2melatoninreceptors AT youssaid newradioligandsfordescribingthemolecularpharmacologyofmt1andmt2melatoninreceptors AT thomasemmanuel newradioligandsfordescribingthemolecularpharmacologyofmt1andmt2melatoninreceptors AT suzenetfranck newradioligandsfordescribingthemolecularpharmacologyofmt1andmt2melatoninreceptors AT folleasbenoit newradioligandsfordescribingthemolecularpharmacologyofmt1andmt2melatoninreceptors AT lefoulonfrancois newradioligandsfordescribingthemolecularpharmacologyofmt1andmt2melatoninreceptors AT berthelotpascal newradioligandsfordescribingthemolecularpharmacologyofmt1andmt2melatoninreceptors AT caignarddanielhenri newradioligandsfordescribingthemolecularpharmacologyofmt1andmt2melatoninreceptors AT guillaumetgerald newradioligandsfordescribingthemolecularpharmacologyofmt1andmt2melatoninreceptors AT delagrangephilippe newradioligandsfordescribingthemolecularpharmacologyofmt1andmt2melatoninreceptors AT brayerjeanlouis newradioligandsfordescribingthemolecularpharmacologyofmt1andmt2melatoninreceptors AT nosjeanolivier newradioligandsfordescribingthemolecularpharmacologyofmt1andmt2melatoninreceptors AT boutinjeana newradioligandsfordescribingthemolecularpharmacologyofmt1andmt2melatoninreceptors |